Microglial ApoD-induced NLRC4 inflammasome activation promotes Alzheimer's disease progression

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disease with no effective therapies. It is well known that chronic neuroinflammation plays a critical role in the onset and progression of AD. Well-balanced neuronal-microglial interactions are essential for brain functions. However, determining the role of microglia—the primary immune cells in the brain—in neuroinflammation in AD and the associated molecular basis has been challenging.

Methods: Inflammatory factors in the sera of AD patients were detected and their association with microglia activation was analyzed. The mechanism for microglial inflammation was investigated. IL6 and TNF-α were found to be significantly increased in the AD stage.

Results: Our analysis revealed that microglia were extensively activated in AD cerebra, releasing sufficient amounts of cytokines to impair the neural stem cells (NSCs) function. Moreover, the ApoD-induced NLRC4 inflammasome was activated in microglia, which gave rise to the proinflammatory phenotype. Targeting the microglial ApoD promoted NSC self-renewal and inhibited neuron apoptosis. These findings demonstrate the critical role of ApoD in microglial inflammasome activation, and for the first time reveal that microglia-induced inflammation suppresses neuronal proliferation.

Conclusion: Our studies establish the cellular basis for microglia activation in AD progression and shed light on cellular interactions important for AD treatment.

Keywords

Alzheimer's disease / ApoD / microglia / NLRC4 inflammasome

References

[1] Reiman EM. Alzheimer disease in 2016: putting AD treatments and biomarkers to the test. Nat Rev Neurol. 2017; 13(2): 74-76.

[2] The Lancet Neurology. Alzheimer's disease: a time for cautious optimism. Lancet Neurol. 2015; 14(8): 779.

[3] The Lancet Neurology. Finding a cure for Alzheimer's disease starts with prevention. Lancet Neurol. 2016; 15(7): 649.

[4] Scheltens P, De Strooper B, Kivipelto M, et al. Alzheimer's disease. Lancet. 2021; 397(10284): 1577-1590.

[5] Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer's disease in the era of biomarkers. Lancet Neurol. 2021; 20(3): 222-234.

[6] Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297(5580): 353-356.

[7] Ossenkoppele R, van der Kant R, Hansson O. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022; 21(8): 726-734.

[8] Deardorff WJ, Grossberg GT. Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother. 2017; 17(1): 17-32.

[9] Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. J Cell Biol. 2018; 217(2): 459-472.

[10] Gosselin D, Skola D, Coufal NG, et al. An environment-dependent transcriptional network specifies human microglia identity. Science. 2017; 356(6344): eaal3222.

[11] Prinz M, Priller J. Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci. 2014; 15(5): 300-312.

[12] Müller S, Kohanbash G, Liu SJ, et al. Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017; 18(1): 234.

[13] Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci. 2007; 10(11): 1387-1394.

[14] Cai Z, Hussain MD, Yan LJ. Microglia, neuroinflammation, and beta-amyloid protein in Alzheimer's disease. Int J Neurosci. 2014; 124(5): 307-321.

[15] Pan RY, He L, Zhang J, et al. Positive feedback regulation of microglial glucose metabolism by histone H4 lysine 12 lactylation in Alzheimer's disease. Cell Metab. 2022; 34(4): 634-648.e6.

[16] Qin Q, Teng Z, Liu C, Li Q, Yin Y, Tang Y. TREM2, microglia, and Alzheimer's disease. Mech Ageing Dev. 2021; 195: 111438.

[17] Olsen I, Singhrao SK. Inflammasome involvement in Alzheimer's Disease. J Alzheimers Dis. 2016; 54(1): 45-53.

[18] Karki R, Man SM, Kanneganti TD. Inflammasomes and cancer. Cancer Immunol Res. 2017; 5(2): 94-99.

[19] van de Veerdonk FL, Joosten LA, Netea MG. The interplay between inflammasome activation and antifungal host defense. Immunol Rev. 2015; 265(1): 172-180.

[20] Man SM, Kanneganti TD. Regulation of inflammasome activation. Immunol Rev. 2015; 265(1): 6-21.

[21] Palomo J, Dietrich D, Martin P, Palmer G, Gabay C. The interleukin (IL)-1 cytokine family—balance between agonists and antagonists in inflammatory diseases. Cytokine. 2015; 76(1): 25-37.

[22] Gordon R, Albornoz EA, Christie DC, et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med. 2018; 10(465): eaah4066.

[23] Krasemann S, Madore C, Cialic R, et al. The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017; 47(3): 566-581.e9.

[24] Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007; 6(8): 734-746.

[25] Liu Y, Yuelling LW, Wang Y, et al. Astrocytes promote Medulloblastoma progression through hedgehog secretion. Cancer Res. 2017; 77(23): 6692-6703.

[26] Brett FM, Kearney H. Neuropathology correlates of cognitive assessments. Ir J Med Sci. 2018; 187(3): 835-844.

[27] Wei Y, Feng J, Hou Z, Wang XM, Yu D. Flow cytometric analysis of circulating follicular helper T (Tfh) and follicular regulatory T (Tfr) populations in human blood. Methods Mol Biol. 2015; 1291: 199-207.

[28] Wimo A. The end of the beginning of the Alzheimer's Disease nightmare: a Devil's Advocate's view. J Alzheimers Dis. 2018; 64(s1): S41-S46.

[29] Sarlus H, Heneka MT. Microglia in Alzheimer's disease. J Clin Invest. 2017; 127(9): 3240-3249.

[30] Jaroudi W, Garami J, Garrido S, Hornberger M, Keri S, Moustafa AA. Factors underlying cognitive decline in old age and Alzheimer's disease: the role of the hippocampus. Rev Neurosci. 2017; 28(7): 705-714.

[31] Malik A, Kanneganti TD. Inflammasome activation and assembly at a glance. J Cell Sci. 2017; 130(23): 3955-3963.

[32] Bajo-Grañeras R, Sanchez D, Gutierrez G, et al. Apolipoprotein D alters the early transcriptional response to oxidative stress in the adult cerebellum. J Neurochem. 2011; 117(6): 949-960.

[33] Li L, Liu MS, Li GQ, et al. Relationship between apolipoprotein superfamily and Parkinson's disease. Chin Med J (Engl). 2017; 130(21): 2616-2623.

[34] Drew L. An age-old story of dementia. Nature. 2018; 559(7715): S2-s3.

[35] Kalaria RN, Maestre GE, Arizaga R, et al. Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors. Lancet Neurol. 2008; 7(9): 812-826.

[36] 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016; 12(4): 459-509.

[37] Perlmutter D. Preventing Alzheimer's Disease. J Am Coll Nutr. 2016; 35(8): 732-733.

[38] Salawu FK, Umar JT, Olokoba AB. Alzheimer's disease: a review of recent developments. Ann Afr Med. 2011; 10(2): 73-79.

[39] Lucke-Wold B, Seidel K, Udo R, et al. Role of tau acetylation in Alzheimer's Disease and chronic traumatic encephalopathy: the way forward for successful treatment. J Neurol Neurosurg. 2017; 4(2): 140.

[40] Correani V, Martire S, Mignogna G, et al. Poly(ADP-ribosylated) proteins in β-amyloid peptide-stimulated microglial cells. Biochem Pharmacol. 2019; 167: 50-57.

[41] Nayak D, Roth TL, McGavern DB. Microglia development and function. Annu Rev Immunol. 2014; 32: 367-402.

[42] Hickman S, Izzy S, Sen P, Morsett L, El Khoury J. Microglia in neurodegeneration. Nat Neurosci. 2018; 21(10): 1359-1369.

[43] Hambardzumyan D, Gutmann DH, Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat Neurosci. 2016; 19(1): 20-27.

[44] Keren-Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's Disease. Cell. 2017; 169(7): 1276-1290.e17.

[45] Regen F, Hellmann-Regen J, Costantini E, Reale M. Neuroinflammation and Alzheimer's disease: implications for microglial activation. Curr Alzheimer Res. 2017; 14(11): 1140-1148.

[46] Schneider J, Karpf J, Beckervordersandforth R. Role of astrocytes in the neurogenic niches. Methods Mol Biol. 2019; 1938: 19-33.

[47] Franklin BS, Latz E, Schmidt FI. The intra- and extracellular functions of ASC specks. Immunol Rev. 2018; 281(1): 74-87.

[48] Liu H, Sun Y, O'Brien JA, et al. Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion. Neuro Oncol. 2019; 22: 625-638.

RIGHTS & PERMISSIONS

2023 The Authors. Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.